Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:investigational_drug
gptkb:small_molecule |
| gptkbp:administeredBy |
oral route
|
| gptkbp:CASNumber |
1693758-51-8
|
| gptkbp:chemicalFormula |
C24H24N6O2
|
| gptkbp:clinicalTrialPhase |
Phase 1/1b
|
| gptkbp:combinationTherapy |
immune checkpoint inhibitors
|
| gptkbp:developedBy |
gptkb:Infinity_Pharmaceuticals
|
| gptkbp:effect |
modulates tumor microenvironment
reduces immunosuppression |
| gptkbp:intendedUse |
gptkb:immunotherapy
|
| gptkbp:mechanismOfAction |
PI3K-gamma inhibition
|
| gptkbp:studiedBy |
solid tumors
advanced cancers |
| gptkbp:synonym |
gptkb:PI3K-gamma_inhibitor_IPI-549
|
| gptkbp:target |
gptkb:PI3K-gamma
|
| gptkbp:bfsParent |
gptkb:PIK3CG
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
IPI-549
|